Podcast: RealPharma: Conversations with Pharma Pathfinders
Episode: Inside the CMC Black Box: A Deep Dive with Reza Oliyai
Hosts: Dr. Na-Ri Oh & Ian Wendt
Original Episode Link: Listen to the episode RealPharma+1
Executive Summary
In this episode, Reza Oliyai—veteran of major pharma manufacturing operations—pulls back the curtain on the “CMC black box” and explains why it is now the primary bottleneck for approval and commercialization. He discusses how sponsors and CDMOs alike must evolve their processes, quality systems, and analytic strategies to keep pace with increasing regulatory scrutiny and complex modalities.
Key Takeaways for CDMOs
- CMC (Chemistry, Manufacturing & Controls) is more than just method development—it now drives regulatory risk and program timing.
- Many late-stage failures are not clinical in nature but manufacturing-/control-system related, especially in outsourced partnerships.
- CDMOs and sponsors must collaborate much earlier—aligning on process readiness, analytics, supply-chain risk, and inspection readiness rather than leaving CMC to later phases.
- For CDMOs, building transparency, audit-readiness, cross-functional quality systems and data-driven controls is no longer optional—it is a differentiator.
CDMOWorld Commentary
From the vantage of CDMOWorld, this episode reinforces a strategic shift: if your CDMO or sponsor treats CMC as a “phase” instead of a continuous system, you are likely entering a risk zone. The future winners will be those who integrate CMC risk governance, analytics, and supply-chain oversight from early development through commercialization.
